Diabetes Risk in Newly Reported Drug Interaction for Pravachol and Paxil

Stanford University researchers recently reported a new drug interaction between paroxetine (Paxil, GlaxoSmithKline) and pravastatin (Pravachol, Bristol-Myers Squibb), which may lead to diabetes in prone individuals, or worsen present diabetes cases.

As reported by Drug Topics, citing May data published online by Clinical Pharmacology & Therapeutics, combining the two allegedly elevates average blood glucose levels by 19 mg/dL overall and by 48 mg/dL in patients with diabetes. Because random blood glucose levels usually fall in the low to mid-100s, the interaction may present a distinct risk to individuals suffering from preliminary or full diabetes.

Lead author for the report Nick Tatonetti told Drug Topics that this instance seems to mark the first occasion that data-mining techniques, usually used to monitor and forecast consumer habits, have been used to pinpoint drug interactions. Researchers searched FDA’s Adverse Event Reporting System (AERS) for claims of ill effects involving glucose homeostasis and made a profile for diabetes-related incidents and followed a long trail of research that eventually led to the pairing of paroxetine and pravastatin.

According to the report, data from electronic medical records at Vanderbilt University and Partners HealthCare showed comparable outcomes. Early studies in mice show a marked interaction between that raises mean fasting blood glucose about 50 mg/dL; a forthcoming study is necessary to validate the interaction, according to researchers.

If you’ve suffered adverse diabetic reactions involving the combination of pravastatin and paroxetine, you may be entitled to compensation for your damages. Call the Pennsylvania Paxil attorneys with Anapol Weiss at 1-866-735-2792 for a free review of your case.

Contact Information